Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lansoprazole: a proton pump inhibitor

W R Garnett1

  • 1Department of Pharmacy and Pharmaceutics, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.

The Annals of Pharmacotherapy
|December 1, 1996
PubMed
Summary

Lansoprazole effectively treats acid-related disorders by inhibiting gastric acid secretion. This proton pump inhibitor is safe and more effective than H2-receptor antagonists, comparable to omeprazole.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical implications of drug interactions with coxibs.

Pharmacotherapy·2001
Same author

Treatment of Crohn's disease with infliximab.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same author

Coprescribing proton pump inhibitors with other medications.

Managed care interface·2001
Same author

Antiepileptic drug treatment: outcomes and adherence.

Pharmacotherapy·2000
Same author

Clinical pharmacology of topiramate: a review.

Epilepsia·2000
Same author

Effect of over-the-counter cimetidine on phenytoin concentrations in patients with seizures.

The Annals of pharmacotherapy·1999

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Proton pump inhibitors (PPIs) are crucial for managing acid-related gastrointestinal disorders.
  • Lansoprazole is an FDA-approved PPI with established efficacy.

Purpose of the Study:

  • To review published data on lansoprazole's efficacy and safety.
  • To summarize its use in treating duodenal ulcers, erosive esophagitis, and Zollinger-Ellison syndrome.

Main Methods:

  • Literature search of MEDLINE (1985-1996) and other relevant sources.
  • Analysis focused on multicenter, double-blind, prospective clinical trials.

Main Results:

  • Lansoprazole inhibits gastric acid by blocking the H+,K+-ATPase proton pump.
  • Clinical trials show lansoprazole is superior to placebo and H2-receptor antagonists.
  • It demonstrates efficacy comparable to omeprazole for various acid-related conditions.

Conclusions:

  • Lansoprazole is a safe and effective treatment for acid-related disorders.
  • It offers advantages over H2-receptor antagonists and is comparable to omeprazole.
  • Treatment choice between lansoprazole and omeprazole may depend on institutional factors and cost-effectiveness.

Related Experiment Videos